146 related articles for article (PubMed ID: 29358180)
21. Delineating domains and functions of NUP98 contributing to the leukemogenic activity of NUP98-HOX fusions.
Yung E; Sekulovic S; Argiropoulos B; Lai CK; Leung M; Berg T; Vollett S; Chang VC; Wan A; Wong S; Humphries RK
Leuk Res; 2011 Apr; 35(4):545-50. PubMed ID: 21130494
[TBL] [Abstract][Full Text] [Related]
22. Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13-driven mouse model.
Xu H; Menendez S; Schlegelberger B; Bae N; Aplan PD; Göhring G; Deblasio TR; Nimer SD
Blood; 2012 Oct; 120(15):3089-97. PubMed ID: 22927245
[TBL] [Abstract][Full Text] [Related]
23. Expression of Leukemia-Associated Nup98 Fusion Proteins Generates an Aberrant Nuclear Envelope Phenotype.
Fahrenkrog B; Martinelli V; Nilles N; Fruhmann G; Chatel G; Juge S; Sauder U; Di Giacomo D; Mecucci C; Schwaller J
PLoS One; 2016; 11(3):e0152321. PubMed ID: 27031510
[TBL] [Abstract][Full Text] [Related]
24. The role of Nup98 in transcription regulation in healthy and diseased cells.
Franks TM; Hetzer MW
Trends Cell Biol; 2013 Mar; 23(3):112-7. PubMed ID: 23246429
[TBL] [Abstract][Full Text] [Related]
25. NUP98 gene fusions in hematologic malignancies.
Lam DH; Aplan PD
Leukemia; 2001 Nov; 15(11):1689-95. PubMed ID: 11681408
[TBL] [Abstract][Full Text] [Related]
26. Regulation of differentiation by a PHD domain in the NUP98-PHF23 fusion protein.
Reader JC; Leng Q; Rassool FV; Ning Y
Leuk Res; 2010 Aug; 34(8):1094-7. PubMed ID: 20219246
[TBL] [Abstract][Full Text] [Related]
27. Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product.
Byrne M; Bennett RL; Cheng X; May WS
Neoplasia; 2014 Aug; 16(8):627-33. PubMed ID: 25220590
[TBL] [Abstract][Full Text] [Related]
28. Expression of the novel NUP98/PSIP1 fusion transcripts in myelodysplastic syndrome with t(9;11)(p22;p15).
Yamamoto K; Nakamachi Y; Yakushijin K; Funakoshi Y; Okamura A; Kawano S; Matsuoka H; Minami H
Eur J Haematol; 2012 Mar; 88(3):244-8. PubMed ID: 22103895
[TBL] [Abstract][Full Text] [Related]
29. A cryptic translocation leading to NUP98-PHF23 fusion in AML.
Ning Y
Best Pract Res Clin Haematol; 2016 Dec; 29(4):320-323. PubMed ID: 27890253
[TBL] [Abstract][Full Text] [Related]
30. MLL is essential for NUP98-HOXA9-induced leukemia.
Shima Y; Yumoto M; Katsumoto T; Kitabayashi I
Leukemia; 2017 Oct; 31(10):2200-2210. PubMed ID: 28210005
[TBL] [Abstract][Full Text] [Related]
31. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes.
Taketani T; Taki T; Nakamura H; Taniwaki M; Masuda J; Hayashi Y
Cancer Genet Cytogenet; 2009 Apr; 190(2):108-12. PubMed ID: 19380029
[TBL] [Abstract][Full Text] [Related]
32. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
33. Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.
Chung YJ; Robert C; Gough SM; Rassool FV; Aplan PD
Leuk Res; 2014 Jan; 38(1):95-102. PubMed ID: 23958061
[TBL] [Abstract][Full Text] [Related]
34. NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function.
Gough SM; Lee F; Yang F; Walker RL; Zhu YJ; Pineda M; Onozawa M; Chung YJ; Bilke S; Wagner EK; Denu JM; Ning Y; Xu B; Wang GG; Meltzer PS; Aplan PD
Cancer Discov; 2014 May; 4(5):564-77. PubMed ID: 24535671
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
36. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
37. Depletion of cytotoxic T-cells does not protect NUP98-HOXD13 mice from myelodysplastic syndrome but reveals a modest tumor immunosurveillance effect.
Gough SM; Chung YJ; Aplan PD
PLoS One; 2012; 7(5):e36876. PubMed ID: 22606303
[TBL] [Abstract][Full Text] [Related]
38. Transformation of human CD34+ hematopoietic progenitor cells with DEK-NUP214 induces AML in an immunocompromised mouse model.
Qin H; Malek S; Cowell JK; Ren M
Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
[TBL] [Abstract][Full Text] [Related]
39. The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.
Saw J; Curtis DJ; Hussey DJ; Dobrovic A; Aplan PD; Slape CI
Leuk Res; 2013 Dec; 37(12):1668-73. PubMed ID: 24090997
[TBL] [Abstract][Full Text] [Related]
40. [HUP98-HOXA9 transgenic mice are susceptible to N-ethyl-N-nitrosourea stimulation in leukemogenesis].
Lu SY; Gu MM; Wang Y; Tan Y; Sun YP; Wang L; Kong H; Lu ZY; Wang ZG
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):257-61. PubMed ID: 15182530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
